[go: up one dir, main page]

WO1999015526A3 - N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives - Google Patents

N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives Download PDF

Info

Publication number
WO1999015526A3
WO1999015526A3 PCT/EP1998/005904 EP9805904W WO9915526A3 WO 1999015526 A3 WO1999015526 A3 WO 1999015526A3 EP 9805904 W EP9805904 W EP 9805904W WO 9915526 A3 WO9915526 A3 WO 9915526A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
disease
pain
epilepsy
neuralgia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/005904
Other languages
French (fr)
Other versions
WO1999015526A2 (en
Inventor
Frank Peter Harrington
Mervyn Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to JP2000512831A priority Critical patent/JP2001517668A/en
Priority to EP98951421A priority patent/EP1017694A2/en
Priority to CA002303994A priority patent/CA2303994A1/en
Publication of WO1999015526A2 publication Critical patent/WO1999015526A2/en
Publication of WO1999015526A3 publication Critical patent/WO1999015526A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

N-(naphthyridinyl)-N'-phenyl-ureas/thioureas of general formula (I) are useful for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
PCT/EP1998/005904 1997-09-19 1998-09-15 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives Ceased WO1999015526A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000512831A JP2001517668A (en) 1997-09-19 1998-09-15 N-5,6,7,8-tetrahydro (1,6) naphthyridine-N'-phenylurea derivative
EP98951421A EP1017694A2 (en) 1997-09-19 1998-09-15 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives
CA002303994A CA2303994A1 (en) 1997-09-19 1998-09-15 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9720052.1 1997-09-19
GBGB9720052.1A GB9720052D0 (en) 1997-09-19 1997-09-19 Novel compounds

Publications (2)

Publication Number Publication Date
WO1999015526A2 WO1999015526A2 (en) 1999-04-01
WO1999015526A3 true WO1999015526A3 (en) 1999-05-20

Family

ID=10819406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005904 Ceased WO1999015526A2 (en) 1997-09-19 1998-09-15 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives

Country Status (5)

Country Link
EP (1) EP1017694A2 (en)
JP (1) JP2001517668A (en)
CA (1) CA2303994A1 (en)
GB (1) GB9720052D0 (en)
WO (1) WO1999015526A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4287649B2 (en) 2000-10-12 2009-07-01 メルク エンド カムパニー インコーポレーテッド Aza- and polyaza-naphthalenylcarboxamides useful as HIV integrase inhibitors
ATE430745T1 (en) 2000-10-12 2009-05-15 Merck & Co Inc AZA- AND POLYAZA NAPHTHALENYL CARBOXAMIDES AS INHIBITORS OF HIV INTEGRASE
ATE345129T1 (en) * 2000-10-12 2006-12-15 Merck & Co Inc AZA- AND POLYAZA-NAPHTHALENYL CARBONIC ACID AMIDES AS HIV INTEGRASE INHIBITORS
EP1432710A1 (en) 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 1, 8-naphthyridine derivatives as antidiabetics
AU2003218130A1 (en) 2002-03-15 2003-09-29 Merck And Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
US8629276B2 (en) * 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
IL283368B2 (en) 2018-11-28 2025-01-01 Takeda Pharmaceuticals Co An imidazo[1,2-b]pyridazin-7-yl-urea compound and a medicine comprising the compound

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1302662B (en) * 1971-02-04
FR2377377A1 (en) * 1977-01-14 1978-08-11 Metabio Joullie Sa AMIDES DERIVED FROM 3,4,5-TRIMETHOXY BENZENE AND THEIR APPLICATION AS MEDICINAL PRODUCTS
EP0105821A1 (en) * 1982-10-05 1984-04-18 Cortial S.A. N-(aminomethyl-5-oxazolin-2-yl-2)-N'-phenyl ureas
US4542144A (en) * 1981-11-16 1985-09-17 Mcneilab Inc. Anticonvulsant N-aryl-N'-(2-thiazolidinylidene)ureas
EP0556008A1 (en) * 1992-02-12 1993-08-18 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives with psychotropic activity
WO1994022807A1 (en) * 1993-04-07 1994-10-13 Neurosearch A/S Urea and amide derivatives and their use in the control of cell membrane potassium channels
WO1996039382A1 (en) * 1995-06-06 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives as 5-ht antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1302662B (en) * 1971-02-04
FR2377377A1 (en) * 1977-01-14 1978-08-11 Metabio Joullie Sa AMIDES DERIVED FROM 3,4,5-TRIMETHOXY BENZENE AND THEIR APPLICATION AS MEDICINAL PRODUCTS
US4542144A (en) * 1981-11-16 1985-09-17 Mcneilab Inc. Anticonvulsant N-aryl-N'-(2-thiazolidinylidene)ureas
EP0105821A1 (en) * 1982-10-05 1984-04-18 Cortial S.A. N-(aminomethyl-5-oxazolin-2-yl-2)-N'-phenyl ureas
EP0556008A1 (en) * 1992-02-12 1993-08-18 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives with psychotropic activity
WO1994022807A1 (en) * 1993-04-07 1994-10-13 Neurosearch A/S Urea and amide derivatives and their use in the control of cell membrane potassium channels
WO1996039382A1 (en) * 1995-06-06 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives as 5-ht antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARCH. PHARM., vol. 330, no. 7, 1997, pages 207 - 210 *
CHEMICAL ABSTRACTS, vol. 67, no. 21, 20 November 1967, Columbus, Ohio, US; abstract no. 99956, XP002095689 *
CHEMICAL ABSTRACTS, vol. 73, no. 13, 28 September 1970, Columbus, Ohio, US; abstract no. 64728, XP002095688 *
HEINISCH ET AL: "Synthesis of N-aryl-N'-heteroaryl-substituted urea and thiourea derivatives and evaluation of their anticonvulsant activity", ARCHIV DER PHARMAZIE, vol. 330, no. 7, July 1997 (1997-07-01), pages 207 - 210, XP002087695 *
M. LAZAROVA ET AL., DOKL. BOLG. AKAD. NAUK., vol. 23, no. 5, 1970, pages 599 - 602 *
N.S. DOBYCHINA ET AL., IZV. TOMSK. POLITEKH. INST., vol. 151, 1966, pages 85 - 87 *
PAVIA M R ET AL: "N-PHENYL-N'-PYRIDINYLUREAS AS ANTICONVULSANT AGENTS1", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 2, February 1990 (1990-02-01), pages 854 - 861, XP000604950 *

Also Published As

Publication number Publication date
WO1999015526A2 (en) 1999-04-01
CA2303994A1 (en) 1999-04-01
GB9720052D0 (en) 1997-11-19
JP2001517668A (en) 2001-10-09
EP1017694A2 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
WO1999015526A3 (en) N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives
CA2401033A1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
PH31123A (en) Benzimidazole compounds.
WO1999045011A8 (en) Glycine transport inhibitors
BR9609019A (en) Active compounds in a new location on receptor-operated calcium channels useful in the treatment of neurological disorders and diseases
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
HUP0003863A3 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
EP1014881A4 (en) Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
IL141263A0 (en) Methods for treatment of neurological disorders
EP0729361A4 (en) Method of treating neurological disorders
AP2000001832A0 (en) Substituted isoquinoline derivatives and their use as anticonvulsants.
ATE526981T1 (en) USE OF VEGF 165 AND HOMOLOGUES TO TREAT NEUROLOGICAL DISORDERS
GB9908175D0 (en) Method of treating neurological disorders
IL160889A0 (en) 4 [piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
AP9901473A0 (en) Use of benzopyranols to treat neurological disorders.
TW200635589A (en) Therapeutic agents
Engum et al. Restandardization of the Cognitive Behavioral Driver's Inventory.
Beale et al. ECT for OCD.
NZ301653A (en) 4-amino substituted tetrahydro-benzisoxazole and tetrahydro-benzisothiazole derivatives; medicaments containing them
PL338242A1 (en) Novel compounds exhibiting an activity promoting differentation of neurones
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998951421

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2303994

Country of ref document: CA

Ref country code: CA

Ref document number: 2303994

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09509148

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998951421

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998951421

Country of ref document: EP